We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
1987
We went public on the Bombay Stock Exchange and launched APIs in India. In the 1980s, we were among the first to export APIs to the USA.
We went public on the Bombay Stock Exchange and launched APIs in India. In the 1980s, we were among the first to export APIs to the USA.
1991
Our first pioneering mega-brand Omez (Omeprazole) was launched in India, becoming our first 100 crore brand and a leader in Indian pharma.
Our first pioneering mega-brand Omez (Omeprazole) was launched in India, becoming our first 100 crore brand and a leader in Indian pharma.
1992
We expanded our operations internationally by opening a branch in Russia.
We expanded our operations internationally by opening a branch in Russia.
1996
Dr. Anji Reddy founded the Dr. Reddy’s Foundation to give back to society. Our CSR activities include health, education, livelihood, and sustainability.
Dr. Anji Reddy founded the Dr. Reddy’s Foundation to give back to society. Our CSR activities include health, education, livelihood, and sustainability.
1997
We were the first Indian pharma company to out-license a novel drug to an innovator.
We were the first Indian pharma company to out-license a novel drug to an innovator.
2001
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
Our founder, Dr. Anji Reddy, received the Padma Shri from the Gov’t of India.
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange.
Our founder, Dr. Anji Reddy, received the Padma Shri from the Gov’t of India.
2002
Aurigene Oncology Ltd, our Bengaluru subsidiary, was incorporated for drug discovery.
Aurigene Oncology Ltd, our Bengaluru subsidiary, was incorporated for drug discovery.
2003
We released our first Safety, Health, Environment (SHE) report. We were also among the earliest to initiate annual voluntary sustainability disclosures from the following year.
We released our first Safety, Health, Environment (SHE) report. We were also among the earliest to initiate annual voluntary sustainability disclosures from the following year.
2006
We became the first Indian pharma company to launch an Authorized Generic (AG) in the U.S. (nasteride 5 mg, generic equivalent of Merck’s Proscar tabs 5 mg).
We became the fastest Indian pharma company to cross USD 1 billion in revenue.
We became the first Indian pharma company to launch an Authorized Generic (AG) in the U.S. (nasteride 5 mg, generic equivalent of Merck’s Proscar tabs 5 mg).
We became the fastest Indian pharma company to cross USD 1 billion in revenue.
2007
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
2010
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
We adopted 6 sustainability goals for the next decade.
We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).
We adopted 6 sustainability goals for the next decade.
2011
Our founder, Dr. Anji Reddy, was honoured with the Padma Bhushan by the Gov’t of India for his contribution to the Indian pharma industry.
Our founder, Dr. Anji Reddy, was honoured with the Padma Bhushan by the Gov’t of India for his contribution to the Indian pharma industry.
2015
Acquired a select portfolio of Belgium based UCBs established brands in certain South Asian countries
Acquired a select portfolio of Belgium based UCBs established brands in certain South Asian countries
2016
We were listed on the Dow Jones Sustainability Index 2016 for Emerging Markets.
We entered the branded consumer health arena through the acquisition of six OTC brands from Ducere Pharma.
We were listed on the Dow Jones Sustainability Index 2016 for Emerging Markets.
We entered the branded consumer health arena through the acquisition of six OTC brands from Ducere Pharma.
2019
We entered the nutrition segment in India with the launch of Celevida, a first-of-its-kind product in Dr. Reddy’s nutrition portfolio.
We were the first foreign generics company to get approval to supply Olanzapine to China's public hospitals under the QCE system.
We entered the nutrition segment in India with the launch of Celevida, a first-of-its-kind product in Dr. Reddy’s nutrition portfolio.
We were the first foreign generics company to get approval to supply Olanzapine to China's public hospitals under the QCE system.
2020
We became the first company in India and third in Asia to join the Science-Based targets initiative (SBTi).
We acquired select divisions of Wockhardt in India.
We became the first company in India and third in Asia to join the Science-Based targets initiative (SBTi).
We acquired select divisions of Wockhardt in India.
2021
Our focus on agility, access and affordability helped us reach over 5 million patients during the pandemic, especially in low and middle income countries.
We combined in-house efforts with open-innovation partnerships to provide a portfolio that included a vaccine and therapeutics for COVID-19.
Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
Our focus on agility, access and affordability helped us reach over 5 million patients during the pandemic, especially in low and middle income countries.
We combined in-house efforts with open-innovation partnerships to provide a portfolio that included a vaccine and therapeutics for COVID-19.
Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
2022
Launched Lenalidomide capsule in the U.S., with two of the six strengths eligible for first-to-market, 180-day exclusivity.
Our Hyderabad facility was recognised by the World Economic Forum as part of its Global Lighthouse Network for Industry 4.0 leadership.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech. We acquired medical cannabis company, Nimbus Health GmbH, in Germany.
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
Launched Lenalidomide capsule in the U.S., with two of the six strengths eligible for first-to-market, 180-day exclusivity.
Our Hyderabad facility was recognised by the World Economic Forum as part of its Global Lighthouse Network for Industry 4.0 leadership.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech. We acquired medical cannabis company, Nimbus Health GmbH, in Germany.
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
2023
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management.
Our platform ‘Celevida Wellness’ became our first D2C e-commerce platform in India carrying our products for diabetes nutrition and third-party brands.
Our proposed rituximab biosimilar dossier was accepted for review by the USFDA, MHRA and EMA.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management.
Our platform ‘Celevida Wellness’ became our first D2C e-commerce platform in India carrying our products for diabetes nutrition and third-party brands.
Our proposed rituximab biosimilar dossier was accepted for review by the USFDA, MHRA and EMA.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
2024
Partnered with Nestle India to launch nutritional health solutions in India and other regions
Acquired Menolabs' women's health and dietary supplements portfolio from Amyris Inc. including seven products for perimenopause and menopause support
Signed a definitive agreement with Haleon Plc to acquire Nicotinell and its Nicotine Replacement Therapy portfolio
Partnered with Nestle India to launch nutritional health solutions in India and other regions
Acquired Menolabs' women's health and dietary supplements portfolio from Amyris Inc. including seven products for perimenopause and menopause support
Signed a definitive agreement with Haleon Plc to acquire Nicotinell and its Nicotine Replacement Therapy portfolio
